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Abstract

Mannheimia (Pasteurella) haemolytica Al is the primary etiological agent of
bovine pneumonic pasteurellosis or shipping fever. The primary goal of this research was
to purify capsular polysaccharides, lipopolysaccharides, and outer membrane proteins of
this organism and to test their strength as antigens against previously generated ascitesform monoclonal antibodies. The secondary goal was to further purify and characterize
the reactive antigen. Outer membrane proteins (OMPs) were the only P. haemoiytica
surface product to show reactivity against 27-1 and 27-1-22 monoclonal antibodies using
immunoblot and ELISA. The reactive OMP was found to be 18kD in size. In order to
further characterize this OMP, affmity chromatography was used. However, these
techniques were not successful in obtaining a pure sample of the 18kD OMP for use in Nterminal amino acid sequencing.
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Introduction

Mannheimia (Pasteurella) haemolytica is the primary etiological agent of bovine
pneumonic pasteurellosis. This disease, commonly referred to as shipping fever, affects
cattle worldwide. In North America alone, it causes losses in the beef and dairy cattle
industries of up to $800 million each year (44). Of primary concern in the cattle industry
is the protection and nourishment of cattle until productive sale. Therefore, it is in the
best interest of those within the industry to find ways to treat and prevent bovine
pneumonic pasteurellosis. The disease is often fatal and develops most commonly in
weaned and yearling cattle that have been transported recently (11). Characterized by
severe, fibrinous pleuropneumonia, the disease is multifactorial and develops in the
complex of bovine respiratory diseases. Development of the disease is usually associated
with various combinations of stress along with infectious agents. The primary infectious
agent of the disease is Mannheimia (Pasteurella) haemolytica. The stresses of cold
weather, shipment, weaning, and overcrowding are most commonly associated with the
disease (15,40). The major infectious stresses include viral agents such as bovine
herpesvirus-l (BHV-l), parainfluenza-3 virus (PI-3), bovine viral diarrhea virus (BVD),
infectious bovine rhinotracheitis virus (IBR), and respiratory syncytial virus (RSV).
BHV-l alters bovine leukocyte functions, BVD causes immunosuppression, and PI-3
increases susceptibility to Pasteurella-induced respiratory disease (5). Colonization of
the lungs with pathogenic bacteria, primarily M haemolytica biotype A, serotype 1 (AI),
is the final causative agent of pneumonic pasteurellosis. Mannheimia haemolytica A2 is
almost always present in the nasal passages of healthy cattle, but it rarely causes
pneumonic pasteurellosis. Al may also be present but not in high numbers (17).
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However, once cattle are shipped, stressed, or infected with a respiratory virus, Al is the
primary organism isolated from the bovine lung. Somehow, stress produces conditions
favoring multiplication of Al in the upper respiratory tract (16).

Mannheimia haemolytica is a gram negative, non-motile, facultatively anaerobic
coccobacillus. It is a member of the family Pasteurellaceae Pohl. Once known as

Pasteurella haemoiytica, A biotypes have now been regrouped into Mannheimia
haemolytica based on I6s rRNA sequencing and DNA-DNA hybridization (2).
However, for the sake of clarity, the Al serotype will be called Pasteurella haemolytica,
with the understanding that the Al serotype is actually now called Mannheimia

haemolytica. The outer surface of the bacterium is made up of potentially antigenic
proteins, polysaccharides, and lipids. P. haemolytica also produces a leukotoxin
(exotoxin) that is produced during logarithmic growth phase, a protease, a neuraminidase,
a thick capsular polysaccharide, a lipopolysaccharide envelope (endotoxin), outer
membrane proteins, and fimbriae (11). Pasteurella haemolytica forms small colonies that
are white to light-gray in color on blood agar and 1 to 3 mm in size. The bacterium
possesses a hemolytic activity producing a weak zone of p-hemolysis beneath the colony
(44). In the genus Pasteurella, now separated into Pasteurella and Mannheimia, there
are two distinct biotypes, characterized by their ability to ferment either arabinose or
trehalose. A biotypes ferment arabinose, while T biotypes ferment trehalose (44). As
previously stated, the primary cause of bovine pneumonic pasteurellosis is serotype AI.
Four major virulence factors have been described. These include the fimbriae, capsular
polysaccharide, lipopolysaccharide, and leukotoxin (9).
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The fimbriae or pili allow the bacteria to adhere non-specifically to the surface
of the upper respiratory tract using surface proteins called adhesins. As a virulence
factor, the most important role offunbriae is to aid in colonization of the upper
respiratory tract, which is a major step in the development of pneumonic pasteurellosis
(9). Two types of fimbriae are produced: a large, rigid nonflexible structure of I2nm
diameter and a small, thin flexible structure of 5nm diameter. Other serotypes of P.

haemolytica are not known to produce fimbriae, identifying this as a virulence factor
(45).
During logarithmic growth, a capsular polysaccharide is produced. The quantity
and thickness of capsule is often greater when grown within an infected calf. The capsule
is also important for adherence to the alveolar and bronciolar surfaces and has a role in
attracting neutrophils to the site of colonization. It may also inhibit phagocytosis and
lysis via neutrophils and complement-mediated cell death (9). The basis for division of
the serotypes of Pasteurella haemolytica is the immunological differences of the capsular
polysaccharide of the different serotypes (3). The structure of the Al capsular
polysaccharide is -7 3)-O-(2-acetarnido-2-deoxy-4-0-acetyl-p-D-mannopyranosyluronic
acid-(l -7 4)-O-(2-acetarnido-2-deoxy-2-D-mannopyranose)-1 -7 (1).
The lipopolysaccharide or endotoxin is the same as that produced by most gramnegative bacteria. LPS is very important in the pathogenesis of the organism. In the
bovine host, it is localized in neutrophils of the alveoli, interstitium, and capillary lumen,
in macrophages of the intravasculature, intestines, and alveoli, in endothelial cells, and on
epithelial cell surfaces (45). It is composed of a cytotoxic lipid A, a core
oligosaccharide, and an antigen polysaccharide chain called the 0 antigen. It has been
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demonstrated to cause direct cell-membrane damage upon bovine pulmonary epithelial
cells, stimulation of leukocyte adherence and infiltration, and vascular damage through
endothelial cell damage (9). The majority of the LPS produced by P. haemolytica is the
smooth type. The lipid A portion has the capacity to activate serine proteases and
therefore the first component of the classical complement pathway (45). The 0 antigen
of the lipopolysaccharide has been characterized as a linear polymer ofa trisaccharide
repeating unit having the structure ~ 3)-P-D-Gal p-(1 ~ 3)-P-D-Gal p Nac-(1 ~ 4)-P-DGal p-( 1~. This same 0 antigen is expressed by many of the A serotypes of P.

haemolytica (38). Furthermore, murine monoclonal antibodies have been used to
demonstrate antigenic similarities among several serotypes of Pasteurella haemolytica
(14). Competitive binding studies have shown the LPS to be a major antigenic
determinant on the surface of the bacteria, but serum antibodies produced in calves after
LPS injection did not seem significant for resistance to subsequent challenge exposure
(10). When observed for its effects upon polymorphonuclear leukocytes (PMN), the LPS
was not toxic. Phagocytosis of infecting cells decreased in the presence of high LPS
concentrations (12).
The most important factor for virulence of P. haemolytica is the leukotoxin
(LKT). It is a chromosomally encoded exotoxin produced during the logarithmic growth
phase and specific for leukocytes of ruminant animal species. Its role in virulence is
primarily directed toward reducing phagocytosis and killing of the bacteria or by causing
lysis of alveolar macrophages and neutrophils within the infected lung (9). It has a
molecular weight of 105 kDa for its major protein component (6). LKT mainly acts upon
susceptible cells by forming large transmembrane pores through which rapid influx of
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Ca2+ may occur (7). Known to be encoded by a four-gene cluster of fktA, [ktE, [ktC, and
[ktD, LktA is the protein ofLKT itself. LktC is required for activation ofLktA, while

LktB and LktD are used for secretion (19). The leukotoxin is designated as an RTX
(repeat toxin) (43). The [ktC gene mutants are equally capable of colonizing the upper
respiratory tract of calves, but appear to be less virulent than wild-type strains under the
same conditions (20). The epitopes involved in neutralization have also been
characterized (22) along with a neutralizing monoclonal antibody to the toxin (18).
The outer membrane proteins (OMP) of Pasteurella haemolytica Al are
important in adhesion to the mucosal surface of the bovine upper respiratory tract (39).
Antibodies to OMP have been demonstrated to be very important in establishing host
immunity to pneumonic pasteurellosis in cattle (28). Major OMP of P. haemolytica have
been shown to alter the activity of bovine neutrophils. This is important because
neutrophils migrate to the lung within hours of the arrival of P. haemolytica. OMP also
inhibit phagocytosis and intracellular killing, allowing the bacteria to proliferate within
the lung (21). Pasteurella haemolytica also has three iron-regulated OMPs that are
expressed only under iron-limited conditions. These three proteins are 71 , 77, and
100kDa in size and show immuDogenicity using sera from calves previously infected
with the organism. These proteins are only expressed in a low iron in vivo environment
(25). Antibodies produced in calves against iron-regulated OMPs in conjunction with
antibodies produced against other surface antigens provide enhanced immunity to
challenge, especially using 70kDa and 77kDa iron-regulated OMPs (8). In another study
a P. haemolytica Al mutant unable to produce three membrane lipoproteins (PlpA, PlpB,
and PIpe) demonstrated increased susceptibility to bovine complement-mediated killing
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when compared with wild-type P. haemolytica. It was concluded that if this mutant were
able to elicit an effective immune response and experience effective clearance by the
host, it may possess attenuation of virulence, making it a possible choice for a live
vaccine (30).
Three P. haemolytica genes (lppJ, /pp2, Ipp3) are known to encode 28-30kDa
membrane proteins (31). Vaccination with the Lpp3 protein elicited the highest immune
response and resistance to pneumonic pasteurellosis according to serum antibody levels
(13). A major 41kDa surface-exposed OMP has also been isolated and characterized. Its
N-tenninal sequence has shown strong homology to a 35kDa porin OMP of Pasteurella
multocida, indicating that the 41kDa OMP is probably a porin OMP as well (23).
Genetic and immunological analysis has been performed upon a 38kDa surface-exposed
OMP as well. Called Lpp38, it is present in both inner and outer membrane fractions of
the cell envelope. It is also recognized by sera from calves resistant to infection either by
natural exposure or vaccination using outer membranes or live bacteria. It is therefore
thought that this protein plays a role in the development of immunity to P. haemoiytica
infection (35). Using the Sarkosyl extraction method, OMPs of30.5, 37, 38.5, 44.5, 49,
62.5, and 82kDa were isolated. This same study compared OMPs of the various
serotypes of P. haemolyfica and found expression of a 43kDa OMP in all of the
serotypes. This 43kDa OMP was thought to be capable of eliciting cross-protective
immunity among the various serotypes (27). Two OMPs of35kDa and 32kDa were
identified as PomA and PomBo PomA demonstrated N-terminal sequence homology with
the OmpA protein of Escherichia coli, but no homologous protein was found for PomB o
Furthermore, sera from cattle vaccinated with live P. haemoiytica developed increased
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serum antibodies to partially purified PomA and to purified PomA and PomB (24). In
another study, three OMPs of31, 40, and 42 kDa were isolated and shown to be antigenic
using sera from calves with prior exposure to P. haemolytica Al (4). Another
lipoprotein, Plp4, 3IkDa in size was also shown to be capable of eliciting an immune
response in cattle (32). In addition, 21 immunogenic, surface-exposed OMPs have been
identified and recognized by bovine antisera from calves resistant to P. haemoiytica
challenge by one of the following methods: natural exposure, vaccination with live P.
haemoiytica, and vaccination with P. haemolytica OMPs. These OMPs were 110, 104,
97,90, 76, 66, 62, 60, 56, 54,47, 39, 38, 36.5, 34, 32, 31.5, 28, 26, 24, and 22.5 kDa in
size (34).
As far as treatment of infected calves, antibiotics are available. One recent trial
tested the efficacy of difloxacin and enrofloxacin, a novel fluoroquinolone, in calves
experimentally infected with P. haemolytica. The study concluded that the two drugs
were equally effective for treating the disease but may not eliminate P. haemolytica from
the host (33). In view of the monetary repercussions and widespread nature of bovine
pneumonic pasteurellosis, the most cost-effective way to at least reduce the occurrence of
this disease is through the development and use of an effective vaccine. Many strategies
have been employed in this effort. These include whole cell bacterin, culture filtrates,
viral vaccines, and combined viraVbacterial vaccines containing P. haemolytica (11).
Most studies have concluded that a mixture of leukotoxin and bacterial surface
components in a subunit vaccine is most effective in eliciting a host immune response
against P. haemolytica (11). Capsular polysaccharide vaccines are largely ineffective and
actually cause disease development, indicating that CPS may playa large part in the
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pathogenesis of the disease (37). Antibodies produced against LPS are also largely
ineffective in providing protection against subsequent exposure to P. haemolyfica. The
same study also indicated that passive immunization with antibodies to whole P.
haemolytica or its LKT -containing supernatants provides protection against experimental
challenge similar to that provided by immunization with the antigenic elements
themselves (29). The use of OMP enriched fractions in a vaccine induced protective
immunity against subsequent P. haemolytica challenge in calves (26). The efficacy of
three commercial vaccines, One Shot, Presponse, and Once PMH, has also been
evaluated. In these trials, One Shot was found to be most effective in reducing the
formation of pneumonic lesions after experimental infection with P. haemolytica (42).
In order to develop an effective vaccine to stimulate protective immunity in cattle,
more study of possible subunit vaccines is required. The goal of this research project has
been to use methods of cell fractionation to isolate the capsular polysaccharides,
lipopolysaccharides, and outer membrane proteins of Pasteurella haemolytica Al and to
test their strength as antigens using monoclonal antibodies produced in mice against live
P. haemolytica injection. A further goal of this study was to attempt to characterize the
surface antigen found to be the most antigenic.
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Materials and Methods

Bacterium

Pasteurella (Mannheimia) haemolytica biotype A serotype 1 (isolate 88-1165),
isolated from the lung of a pneumonic calf, was provided by Dr. Robert D. Walker
(Michigan State University, East Lansing, MJ). The organism had been passed two times
in calves by intrapulmonary inoculation, re-isolated, and stored in skim milk at -80
degrees Celsius (C). In vitro passage of the organism was carried out at 37 C in brain
heart infusion broth (BID, BBL, Cockeysville, MD).

Cell Culture
A hybridoma cell line previously generated from the fusion of mouse
spleenocytes to SP2-0 cells was used in the generation of the 27-1-22 antibody in cell
culture (47). The cells were cultured in Dulbecco's Modified Eagle's Medium (DMEM)
supplemented with 10% fetal bovine serum (Atlanta Biologicals, Atlanta, GA), 2000
units (U) penicillinl2 milligram (mg) streptomycin per liter of medium, 40 millimolar
(mM) L-glutamine (psg: Sigma) and 0.2% sodium bicarbonate (NaHC0 3 : Mallinckrodt,
Paris, KY) at 37 C in an atmosphere of5% CO 2 in the air. Cells were propagated by
splitting 1: 10 into fresh medium every four days.

Outer Membrane Protein Preparation
The outer membrane proteins of P. haemolytica were isolated by a modification
of the methods ofRapp, et af (45), Brennan, et af (33), and Squire, et af (45). 100
microliters (fll) of frozen stock P. haemolytica in BID and glycerol were inoculated into
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10 milliliters (ml) ofBHI broth and incubated overnight at 37 C in a shaking water bath
(Orbit Environ-Shaker, Lab-Line Instruments Inc., Melrose Park, IL) at 225 revolutions
per minute (rpm).

SOO~1

of this overnight culture was then inoculated into SOml ofBHI

broth. This was then placed in a shaking water bath at 37 C at 22Srpm for 4-6 hours, the
predetermined time to reach logarithmic growth phase. The cells were then harvested by
centrifuge at 14,SOO x gravity (g) for 20 minutes at 4 C. The supernatant was discarded
and the pellet was resuspended in 20ml of 10 mM HEPES buffer (N-2Hydroxyethylpiperazine-N' -2-Ethanesulfonic acid, United States Biochemical
Corporation, Fair Lawn, NJ, pH 7.4). Using a sonicator (Sonic Dismembrator, Fisher
Scientific, Tustin, CA) set at SO% max output, the cells were disrupted with 3 to S bursts
for 20 seconds each, with 20 second rests in between, while cooling the tube in an ice
bath. Whole cells and insoluble debris were removed by centrifuge at 2S00 x g for 20
minutes at 4 C. The supernatant was transferred to fresh centrifuge tubes to pellet the
total membrane fraction at 100,000 x g for 60 minutes at 4 C. The supernatant was
discarded, and the pellet was resuspended in 8ml of 1% Sarkosyl (Fisher Biotech, Fair
Lawn, NJ) and allowed to incubate for 30 minutes at room temperature to selectively
solubilize the inner membrane. The outer membrane proteins were pelleted at 100,000 x
g for 60 minutes at 4 C. After discarding the supernatant, the pellet was resuspended in 4
ml of deionized water (dH 20) and stored at 4 C until used.

Lipopolysaccharide Preparation
The lipopolysaccharide preparation was isolated according to the method of Staub
(43). 100111 of frozen stock P. haemolytica in BHI and glycerol were inoculated into 10ml
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ofBHI broth and incubated overnight at 37 C in water with shaking at 225 rpm. 500: I of
this overnight culture was inoculated into 50ml ofBHI broth. This culture was placed in
a shaking water bath at 37 C at 225rpm for 4-6 hours to reach logarithmic growth phase.
The cells were then harvested by centrifugation at 7000 rpm for 30 minutes at 4 C. The
whole cells were washed twice with a 0.85% saline solution at 7000 rpm for 30 minutes
at 4 C. The cells were then weighed and suspended in a volume of 4 C dH 20 equal to
five times their wet weight. An equal volume of trichloroacetic acid (TCA) was then
added, and the mixture was shaken. The mixture was then cooled in an ice bath for 3
hours. After allowing the mixture to warm to room temperature, it was centrifuged at
7000rpm for 30 minutes at 4 C. The pellet was discarded. The supernatant was then
neutralized to pH 6.5, first with 1 molar (M) NaOH and then with O.IM NaOH. The
supernatant was then cooled to 4 C in an ice bath. Precipitation was done by pouring the
cold supernatant into 2 equal volumes of95% ethanol cooled to -10 to -15 C in an ice
bath. It was allowed to stand at 4 C overnight in a sealed container. The mixture was
then centrifuged at 4 C at 7000 rpm for 30 minutes. The pellet was dissolved in 10% of
the original volume with dH20 and neutralized to pH 7. The solution was dialyzed using
dialysis tubing with a molecular weight cutoff value of 12,000 to 14,000 (SpectraiPor,
Spectrum, Gardena, CA) for 3 days at 4 C against 4 L of 0.1 M MgCl, changing the
dialysis solution every 24 hours. The dialysis product was centrifuged at 27,000 x gat
4 C for 30 minutes, and the pellet was discarded. The supernatant was then freeze-dried
for 2 days. The [mal product was then stored at 4 C until ready for use.
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Capsular Polysaccharide Preparation
The capsular polysaccharide was prepared by the method of Adlam (1). IOOl-llof
frozen stock P. haemolytica in Bill and glycerol were inoculated into 10mI of Bill broth
and incubated overnight at 37 C in a shaking water bath at 225 rpm. 500lliofthis
overnight culture was then inoculated into 50mI ofBHI broth. This was then placed in a
shaking water bath at 37 C at 225rpm for 4-6 hours to reach logarithmic phase. The
culture was then heated at 60°C for 1 hour and 0.2% formalin was added. The cells were
removed by centrifugation at 9500 x g for 20 minutes at 4°C. The supernatant was
retained and concentrated to 1/50 of the original volume using an Amicon <10,000
molecular weight cut-off filter. Three volumes of methanol and sodium acetate were
added to the concentrated supernatant. The precipitate formed was allowed to settle at
4 C overnight and was discarded. The methanol supernatant was filtered using a 0.2
micrometer (f!m) Millipore membrane filter. Three volumes of acetone were then added.
The precipitate formed was allowed to settle and the supernatant was discarded. The
precipitate was resuspended in dH 20 and lyophilized in dry ice. 1 g of the lyophilized
precipitate was dissolved in 1/10 saturated Sodium Acetate (NaOAc) (50ml) + 77%
phenol (25ml) and shaken for about 2 minutes. The phases were then split by
centrifuging at 13,500 x g for 1 hour at 4 C. The resultant phenol phase was re-extracted
as above three times more with fresh NaOAc, and the phenol phase was discarded. The
pooled aqueous phase was then dialysed against 4 liters (L) ofO.1M CaCh for 24 hours,
changing the dialysis solution after 12 hours. The dialysed solution was centrifuged at
100,000 x g for 3 hours at 4 C, and the ethanol supernatant was discarded. The
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precipitate was washed in ethanol and frozen in dry ice. This frozen product was then
lyophilized and stored at 4 C until used.

Western Immunoblot
Protein preparations were run on sodium dodecyl sulfate-polyacrylamide gel
electrophoresis (SDSIP AGE) using a Mini Protean II gel apparatus (Bio-Rad). Stacking
gels of 4 to 10% and separating gels of 10 to 18% (acrylamidelbisacrylamide 30:0:8;
National Diagnostics, Atlanta, GA) were used. Protein preparations were adjusted to
desired concentration in phosphate buffered saline (PBS), pH 7.4 and 2X sodium dodecyl
sulfate (SDS), pH 6.8 sample buffer and electrophoresed from 120 to 240 minutes at a
constant current of 14rnA.
The SDSIP AGE gels were then soaked in protein transfer buffer consisting of
0.025M tris base (PH 8.2; Sigma), 0.19M glycine (Fisher) and O.IM SDS. The proteins
in the gel were transferred to Immobilon-P polyvinylidene difluoride (PVDF) membranes
(Millipore) using a semi-dry protein transfer apparatus (Gelman) at 175 rnA for 2 hours.
Vacant protein binding sites were then blocked using 3% Nonfat Dry Milk (Carnation
Co., Los Angeles, CA) in tris-buffered saline (TBS) at 37 C, gentle agitation for 1.5
hours. After two 15 minute rinse cycles in fresh TBS-0.05% Tween-20 (Sigma) at room
temperature, proteins of interest were bound using primary antibody of2% ascites-form
antibody in TBS. This primary antibody solution was added to the membrane under
gentle shaking for 1.5 hours at 37 C or overnight at room temperature. The membrane
was then rinsed with fresh TBS-0.05% Tween-20 as outlined above. Protein bands
bound by the specific antibody were visualized by adding a 1:2000 solution of
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horseradish peroxidase-conjugated protein G (HRP-protein G) prepared in TBS. Protein
G bound to the heavy chain of immunoglobulin (antibody) molecules. The membrane
was soaked in this solution with gentle shaking for 1.5 hours at 37 C. Rinsing was then
done as stated above. A developing solution was prepared using a mixture ofBiorad
HRP color development reagent, methanol, TBS, and 30% H2 0 2 . After about 30 minutes
of gentle shaking, the development was terminated by washing the membrane in dH 20,
leaving insoluble black color bands where the HRP-protein G had bound to antibody
molecules. Since the antibody bound to a specific antigen protein band, this process
visualized and identified proteins to which the antibody reacted specifically.

SDS-PAGE Coomassie Blue Staining
To visualize proteins in the SDSIPAGE gel or PVDF membrane, the membrane or
gel was soaked in 0.50% Coomassie Brilliant Blue R-250 (BioRad) in 5% methanol and
7.5% acetic acid (Mallinckrodt) at room temperature until the gel or membrane was
saturated with staining solution. The membrane or gel was then destained by soaking in
40% methanol and 10% acetic acid in dH 20 at room temperature until stained protein
bands could be visualized upon the membrane or gel.

Dot-Blot Test
The dot-blot apparatus was set up using the same PVDF membrane used for
Western Blots. 1110 dilutions of whole washed P. haemoiytica cells, LPS, CPS, OMP,
leukotoxin, and 2% wt bovine serum albumin (BSA) in dH2 0 were loaded onto the
apparatus and applied to the membrane using vacuum force for 2 minutes. The
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membrane was then removed in four segments and treated with four primary antibodies
ofascites-fonn monoclonal antibodies 27-1,27-1-22,22-2-87, and 27-18-103. The
incubation time, secondary antibody application, and development were the same as
described for the Western Blot protocol.

Direct ELISA
Using Falcon Pro-Bind 96-well flat bottom microtiter plate (Falcon, BecktonDickinson, Franklin Lakes, N.J), 50f,!1 of each (whole cells, CPS (1/1 0 dilution), LPS
(1/10 dilution), OMP (1/10 dilution), leukotoxin (2%), and BSA (2%» were applied and

the plate was allowed to dry overnight. The plate was then blocked with 2% gelatin in
dH20 at 200f,!i per well. The plate was covered and placed in a humid chamber to rotate
at 37 C for 1.5 hours. It was then rinsed three times with TBS-O.OS% Tween-20. The
plate was then divided into four sections and treated with primary antibody of2% crude
ascites of27-1, 27-1-22,22-2-87, and 27-18-103 in respective sections ofthe microtiter
plate at 50f,!1 per well. The plate was placed in the humid chamber to rotate at 37 C for
1.S hours and then rinsed as before. Secondary antibody of 1:2000 HRP conjugated

protein G was then added to each gel at SOf,!1 per well, and the plate was then placed in
the humid chamber to rotate at 37 C for 1.S hours. Rinsing followed as before and
development of the assay was done using the previously described ZYMED kit (ABTS
for HRP) for 30 minutes in the dark. After development, the plate was analyzed using a
microtiter plate reader (Spectra-Max 340, Molecular Devices) set to read solution
absorbance at 405 nanometers (nm) light wavelength
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(~05).

Wells with higher

absorbance indicated higher concentrations of binding of the primary ascites antibodies to
the tested antigen.

Large Scale Preparation of Antibody Supernatant
From a viable hybridoma cell culture of the 27-1-22 antibody, 6 ml of the cell
culture contained in a 25 cm2 small flask were transferred to a 75 cm2 flask containing
23mL of fresh DMEM media described earlier. After 24-48 hours of incubation, 30ml of
fresh media were added. When the ceUs were then ready to be supplied with fresh media,
the content of the 75 cm2 was transferred to a roller bottle containing 90ml of fresh
media. Fresh media was subsequently added in 150ml increments each day for 3 days
followed by 300ml increments for 2 days, followed by a 600ml fresh media addition on
the following day. After this culture had reached the desired growth level, turning the
media a bright orange color, the supernatant medium was harvested by transfer to
centrifuge bottles with subsequent centrifugation at 3000 rpm for 15 minutes at 4 C. The
supernatant medium was then filtered using Millipore 0.021lm Stericaps (Millipore
Corporation, Bedford, MA). The filtered supernatant was stored at 4 C and used within
48 hours.

Purification of27-1-22 antibody
The 27-1-22 antibody was purified by affmity chromatography using Rat-Anti
Mouse Kappa light chain antibodies bound to Sepharose 4B (ZYMED). This sepharose
matrix was packed in a BioRad affmity chromatograpy column according to
manufacturer's directions. All work with the affmity column was perfomed at 4 C. First,
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PBS was passed through the column for three complete bed volumes. The supernatant
containing the antibody was passed through the column using a peristaltic pump
(Pharmacia, Piscataway, NJ) in lL increments. After each liter, three column volumes of
PBS were passed through the column to remove unbound antibody. Next, an eluting
buffer ofO.1M Sodium Citrate, pH 2.6 was passed through the column and collected in
1m! increments, each combined with 6 drops of neutralizing buffer (1M Potassium
phosphate dibasic, pH 8.0). Each aliquot was then analyzed at A280, and those with
absorbance readings of 0.1 or greater were reserved and stored at 4 C for future use.

Purification of monoclonal antibody 27-1-22
Using a Gamma bind column (protein G column) (Zymed, San Franscisco, CA)
and the following protocol, the monoclonal antibody 27-1-22 was purified from ascites
fluid and concentrated. The column was first equilibrated with 10 column volumes of
washing/binding buffer (O.OIM Sodium phosphate, pH 7.0 and 0.15M Sodium chloride).
The ascites sample volume of 10ml was then allowed to pass through the column to allow
affmity binding of antibodies to the bound protein G. Next, the column was washed
using the washing/binding buffer for about 10 column bed volumes to rinse unbound
ascites proteins. The bound antibodies were then eluted from the column using eluting
buffer (0.5M Ammonium acetate, pH 3.0). The eluent was neutralized with 0.55m1 of
neutralizing buffer (lM Tris, pH 9.5) per mI of eluted fluid. Eluted samples with A 280 of
0.1 or greater were reserved for future use.
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Purification of Antigenic 18kD Outer membrane protein by EAR Sepharose Method
An affmity chromatography column was constructed using EAR Sepharose 4B
(Pharmacia) according to the directions provided by the manufacturer using N-ethyl-N'(3-dimethyl-aminopropyl) carbodiimide hydrochloride (EDe) to couple the antibody or
asciety to the matrix. Two columns were constructed; one with 27-1-22 purified antibody
produced by the hybridoma cells and one with 27-1-22 monoclonal antibody purified
from crude ascites. Three bed volumes of PBS were passed over each column to pack the
matrix. This was followed by three bed volumes of binding buffer (lOmM phosphate, pH
6.8). Sterile-filtered outer membrane protein preparations were then passed over the
column and allowed to bind. Three bed volumes of PBS were then passed over the
column to remove any unbound P. haemolytica outer membrane proteins. The following
buffers were used in the same fashion as the previously mentioned affmity
chromatography methods: eluting buffer (I OOmM glycine, pH 2.5) and neutralizing
buffer (l/20 vol 1M phosphate, pH 8.0). Elutions were taken as before and analyzed at
A 2so.

Purification of 18kD Outer Membrane Protein by Kappa Light Chain Column Method
The previously constructed Kappa Light Chain column was used at 4 C. First
PBS was passed through the column for three complete bed volumes. The supernatant
containing the antibody was passed through the column using a peristaltic pump in lL
increments. After binding the antibody the column, the unbound antibody was removed
from the column using three complete volumes of PBS passed through the column. Next,
a dilute sample of purified outer membrane protein in dH 20 (0.01255 mg/ml) was passed
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through the column to allow the 18kD antigenic protein to bind to the 27-1-22 antibody
that had already bound to the column. The column was then rinsed of unbound outer
membrane proteins using five bed volumes of PBS passed through the column. The
column was eluted using Sodium Citrate, pH 2.6 in 1ml increments, each combined with
6 drops of neutralizing buffer (lM Potassium Phosphate dibasic, pH 8.0). These elutions
were analyzed for quality at A28o .
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Results
Cell Fractionation
The outer membrane proteins, capsular polysaccharides, and lipopolysaccharides
of Pasteurella haemolytica were purified and stored as previously described. Using the
Dot-Blot test and the Direct Elisa, the outer membrane proteins were the only surface
antigens to show reactivity against 27-1 and 27-1-22 ascites-form monoclonal antibody.
The other surface antigens showed little or no reactivity against the four ascites-form
monoclonal antibodies. The photograph of the Dot-Blot test result is shown in figure 1,
followed by the analysis ofthe Direct Elisa produced by the microtiter plate reader in
figure 2

Outer Membrane Protein Purification and Analysis
The outer membrane proteins of Pasteurella haemolytica were purified as
previously described. Using the BCA analysis, the concentrations of these protein
preparations were also detennined and recorded. The BCA analysis results for the protein
purifications are shown in figure 3. SDS-PAGE and Western Blot were used to detennine
the size and antigenic nature of the proteins. The major antigenic protein was detennined
to be 18kD in size. Using Western Blot, it was recognized by the 27-1 and 21-1-22
ascity-fonn monoclonal antibodies. Figure 4 is a list of all the Western Blots and
SDS-PAGE gels performed upon the purified OMPs. This figure also includes the date of
each blot or gel, the percentage of polyacrylamide, the concentration of the outer
membrane proteins, and the primary antibody treatment. The photographs of the Western
Blots and SDS-PAGE gels are shown in figures 5 through 9.
After first isolating the 18kD OMP upon the Millipore O.221lm membrane, the
membrane was sent to Dr. Charles Murphy, University of Tennessee Medical Center, for
N-terminal sequencing. This sequencing effort indicated that the preparation was not
clean, so further attempts were made to purify the protein using the method previously
22

described. These efforts were unsuccessful. In another attempt to purify the 18kD
antigenic OMP, it was decided that affinity chromatography would be used.

Affinity Chromatography Using Hybridoma-Secreted 27-1-22 Antibody
Using a viable hybridoma cell culture of the 27-1-22 antibody, a large-scale
preparation was grown over the course of a few weeks. This supernatant of this
hybridoma cell culture was filtered by the method previously described. Because the
supernatant contained the 27-1-22 antibody produced by the hybridoma, it was passed
over a Rat-Anti Mouse Kappa Light Chain column. The eluent from this affinity
chromatography was preserved for future use. This eluent was tested for size using an
SDS-PAGE gel, shown in figure 10. This was also used to prove that the hybridoma cell
line was viable and secreting antibody. In the figure, the heavy and light chains can be
seen. To ensure that the column was working efficiently and purifying kappa chain
antibody, an anti-lambda Western Blot assay was used. The results of this assay are
shown in figure 11. This shows that the purified antibody was a kappa light chain
antibody. To test for the binding capability of the purified 27-1-22 antibody to the OMPs,
an SDS-PAGE gel and Western Blot using the ascity-form and hybridoma-produced
27-1-22 antibodies as the primary antibody treatments. The results ofthese tests are
shown in figures 12 and 13. This confirmed that the Kappa light chain column was
effectively purifying the 27-1-22 antibody.

Purification of Antigenic 18kD Outer Membrane protein by EAH Sepharose Method
This affinity chromatography column was constructed as previously described.
The elutions from these two columns produced very disappointing results. The elutions
were analyzed at A 280 , and the results are shown in figure 14.
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Purification of Antigenic] 8kD Outer Membrane Protein by Kappa Light Chain Method
This affinity chromatography column was used in the hopes of simultaneously
purifYing 27-1-22 antibody and outer membrane proteins. The Kappa light chain column
was used as previously described to purify the 18kD antigenic outer membrane protein.
The elutions were analyzed at A 280 , and the results are shown in figure 15. These
elutions along with the outer membrane proteins that flowed through this affinity
chromatography column were used in a Western Blot. In this particular blot, the primary
antibody treatment used was purified 27-1-22 ascity-form monoclonal antibody. The
secondary antibody treatment used was HRP-Protein G. This Western Blot is shown in
figure 16. In a further attempt to isolate the antigenic 18kD OMP upon the Millipore
membrane for N-terminal sequencing, a Western Blot was performed to bind the OMP to
the membrane and lightly stain the membrane with Coomassie Blue stain. This was done
using 8% stacking and 10% separating gels. The results of this blot are shown in figure
17.
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Figure 1 - Dot-Blot (lmmunoblot) Analysis

LPS
9 C: 59
27-18-193

22-28?

27-1-22

27-1

Immunoblot showing reactivity of outer membrane proteins with 27-1 and 27-1-22 ascites.
BSA-bovine serum albumin
CPS-capsular polysaccharide
OMP-outer membrane protein
Lkt-leukotoxin
LPS-lipopo lysaccharide
Whole cells-Pasteurella haemolytica whole cells
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Figure 2 - ELISA analysis
TableofAbsomance Vahles
~ocehOTide

Whole Ce/ls
27-/
27-/
27-/-22
27-/-22
27-2-87
27-2-87
27-/8-/03
27-/8-/03

A
8
C
D

E
F
G
H

1

2

3

4

0.031
0035
0.045
0.057
0.052
0.062
0.351
0.338

0.018
0.017
0.023
0.017
0.021
0.035
0.280
0.529

0.027
0.028
0.038
0.056
0037
0.050
0.787
0.784

0.004
0.009
0.014
0.013
0.015
0.022
0.814
0.924

l eukotoxin
5
-0.001
0.003
0.002
0.001
0.016
0.031
0.823
1.046

6
0.001
0.003
0000
-0.003
0.002
0.017
0.688
0.476

OM I'ro/eill
7
1095
1953
1.964
2.105
0.086
0.090
2.144
2.517

8
1009
1695
1978
2039
0.069
0.063
2.059
2.388

COD.!u/or I'o/y.me. Rovme Serum A/humin
9
10
1l
12
-0.007
-0.010
-0003
-0.003
-0.008
0.005
0.170
0.188

-0.010
-0.008
-0.007
0.149
-0.003
-0025
0.171
0.062

-0.012
-0.011
0.013
0000
-0.005
0.000
0.155
0.016

0.017
0.007
0.003
-0.003
-0001
0.004
0.007
0.013

ELISA analysis showing absorbance values for each of the indicated substances. Also
shown is the high affinity of outer membrane proteins for 27-1 and 27-1-22 ascites, based
upon absorbance values.
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Figure 3 - Outer membrane protein purifications
Outer Membrane Protein Purifications
Date Purified

5117/0.0.
6/2/0. 0.
6/2110.0.
711110.0.
7 / 17 / 0.0.
7 /20. / 0.0.
7/24/0.0.
7 /26/0.0.
811 / 0. 0.
8/2 / 0. 0.

Concentration (m f! l m I)

0. .580.
0..448
0. .925
2.670.
2 .767
5 .671
4.788
3.4 4 7
1 .830.
2 .5 J 0.

Each outer membrane protein purification concentration is listed by date

Figure 4 - List of Western Blots and SDS-PAGE gels performed
We.wmllas 1ft!sa;..PA(E GdsforlUer M:nimne PtrXtim
~

5
6
7
8
9

frteriPeifcmure Te!JTw ~ Sermiirg% QM'Cin:£rtroJia1(mil7ii
12!7I9)WSfmIb
4"10
10'/. 0..338 !Ill o..184
1131/00 WSfmfb
10'/ .
IWloo.338!1l1o..l84
W/.
1Plo 0..338 !Ill 0.327
W/.
IP/.o.338, 0..327, !Ill 0..514
8%
15% 0..327 !Ill 0..514

27

PrinuyArtilxxfv TT"f!l1rrFnl q- Stan
21-1, 27-1-Z2, !Ill Oxrm;sie Slain
27-1, 27-I-Z2, !IlIOxrm;sieSlain
27-1, 27-I-Z2, !Ill Oxrm;sie Slain
~Stai1

27-1, 27-I-Z2, !Ill Gxnm;ie Slain

Figure 5 - Western blot of outer membrane proteins

-12

c:

114:91

59

12/9719'

Rainbow
laddel

--

-

46kO

-

JOkO

- ---

21.5kD

Z7-(

Western blot showing an 18kD outer membrane protein binding to 27-1 and 27-1-22
ascites. CB refers to Coommassie blue staining of the membrane.
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Figure 6 - Western Blot of outer membrane proteins

Western blot showing an 18kD outer membrane protein binding to 27-1 and 27-1-22
ascites. CB refers to Coomassie blue staining of the membrane.
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Figure 7 - Western blot of outer membrane proteins

Western Blot showing an 18kD outer membrane protein binding to 27-1 and 27-1-22
ascites. CB refers to Coomassie blue staining of the membrane.
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Figure 8 - SDS-PAGE gel of outer membrane proteins

SDS-PAGE gel showing the outer membrane protein purification separated according to
size. The protein of interest is shown to be 18kD in size.
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Figure 9 - Western Blot of outer membrane proteins

Western Blot showing an 18kD outer membrane protein binding to 27-1 and 27-1-22
ascites. CB refers to Coomassie blue staining of the membrane.
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Figure 10 - SDS-PAGE gel of 27-1-22 ascites and Kappa column eluent

27-1-22

old
27-1-22

stJpelcatant

I

I

The heavy and light chains can be visualized at 46kD and 20kD_ This gel was used to
prove that the hybridoma cell line was viable and actively secreting antibody_
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Figure 11- Western Blot of 27-1-22 ascites and eluent
27-1-22 asc~es

(

I
27-'·22
supernatant

Rainbow
Ladder

Western blot showing that the 27-1-22 was not a lambda light chain antibody.
Anti-lambda purification was the primary antibody treatment. Reactivity of the ascites is
most likely due to the presence of fetal bovine serum.
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Figure 12 - SDS PAGE gel of outer membrane proteins

SDS-PAGE gel of outer membrane proteins, showing the protein of interest to be 18kD in
SIZe.
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Figure 13 - Western blot of outer membrane proteins

Western blot showing binding of18kD outer membrane proteins to 27-1-22 ascites,
eluent, and unpurified supernatant.
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Figure 14
EAR Sepharose Column Results

ascity
0.019
0.041
0.024
0.005
0.000

antibodv
0.008
0.060
0.019
0.008
0.004

Absorbance values for elution of ascity and antibody from the EAH Sepharose affinity
column

Figure 15
Kappa Light Chain Method

elution
-0.011
0.325
0.203
0.052
0.020
Absorbance values for dual elution of outer membrane protein and 27-1-22 antibody from
the Kappa Light Chain affinity column.
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Figure 16 - Western Blot of eluent from dual elution method

column

elution

This Western Blot shows binding of outer membrane proteins, in both the elution and
column flow through, binding to 27-1-22 ascites.
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Figure 17 - Light Coomassie Stain of outer membrane proteins and the
dual method affinity column elution

OMP/27-'-22
column elution

I

LowMW

Ladder

This light Coomassie stain shows the 18kD outer membrane protein and the size
distribution for the OMP/27-1-22 column elution_
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Discussion

Cell Fractionation
After purification of outer membrane proteins, capsular polysaccharide, and
lipopolysaccharide, the outer membrane proteins were the only surface antigens to react
with ascites-form monoclonal antibodies 27-1 and 27-1-22 in Direct ELISA and Dot-Blot
tests. Therefore, study was concentrated upon outer membrane proteins and their value
as surface antigens of Pasteurella haemolytica AI. In order to further study the OMPs,
many protein purifications were made according to the method previously stated.

Outer Membrane Protein Analysis
The concentration of each protein purification was determined using the BCA
analysis. The primary mode of analysis for the OMPs was the Western Blot and SDSPAGE. These two tests allowed for the discovery of the size of the major antigenic
protein and its respective antibody. From the results obtained it was decided that SDSPAGE gels should be 8% stacking and 15% separating for optimal migration of the 18kD
OMP of P. haemolytica. Variation in the concentration of the OMP loaded onto the gel
or Western Blot seemed to have little effect upon the results obtained. The major
antigenic protein was found to be 18kD in size and reactive against 27-1 and 27-1-22
ascites-form monoclonal antibodies, as shown by the photographs of the blots and gels.
Therefore, the rest of the study was thereafter concentrated upon further purifying this
particular OMP and isolating it for N-terminal sequencing, so as to more specifically
characterize this specific antigenic protein.

40

Because the first sequencing effort by Dr. Charles Murphy was unsuccessful,
further attempts were made to purify the protein using the methods previously described.
Because these efforts were not effective, it was decided that affinity chromatography was
necessary to specifically isolate the antigenic protein of interest.

Purification and Analysis of 27 -1-22 Antibody
Although the protein antigen bound to both the 27-1 and 27-1-22 type antibodies,
the 27-1-22 type antibody was chosen for further study because of its availability in the
form of a hybridoma cell culture. This antibody type was grown in large quantities from
a viable hybridoma cell culture previously produced by Don Gerbig (18). The eluent
derived from the use ofthe Rat-Anti Mouse Kappa Light Chain column was found to
contain both heavy and light chains, demonstrating that antibody was purified using the
column (figure 10). This also demonstrated that the hybridoma cell line was in fact
secreting antibody. However, this was not conclusive because of the presence oftetal
bovine serum in the hybridoma supernatant. Figure 11 was used to prove that the 27-122 antibody was a kappa chain antibody. This test was necessary because ofthe low
elution yields produced by the Kappa chain affmity column. The Western Blot shown in
figure 11 identified no lambda light chain antibodies using the anti-lambda primary
antibody treatment. The problems with purification of significant levels of the 27-1-22
antibody were thought to be linked to problems with the pH of the elution buffer or low
levels of antibody production by the hybridoma cell line.
Figures 12 and 13 show attempts to determine if the antibody being purified with
the Kappa light chain affmity column was reactive with the purified outer membrane
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proteins of interest. The SDS-PAGE gel was performed to test the quality of the OMP
samples and to use for comparison with the results of the Western Blot. From the SDSPAGE gel, it was evident that the protein of interest had not suffered degradation.
Column-purified 27-1-22 was also loaded onto this gel, but produced no visible bands of
sizes indicating the presence of heavy or light chain immunoglobulins. The Western Blot
was designed to test for reactivity of the outer membrane proteins with the purified 27-122 antibody. From this test, it was evident that at least some antibody was being purified
by the column, since there was clear reactivity between the 18kD OMP and the columnpurified 27-1-22 antibody.

Purification and Analysis of Antigenic 18kD OMP using EAR Sepharose Method
The elutions from the two EAR Sepharose affinity chromatography columns
produced disappointing results, as shown in figure 14. Reasons for the failure of these
two affmity columns could include such reasons as ineffective binding of the antibody to
the Sepharose 4B gradient, ineffective capture of the antigenic OMP by the 27-1-22
antibody, or failure of the binding or elution buffer to function properly. Because of the
failure of this attempt and its time-consuming nature, this method was abandoned for the
Kappa light chain method.

Purification and Analysis of Antigenic 18kD OMP using Kappa Light Chain Method
In the hopes of simultaneously purifying the 27-1-22 antibody and OMP, this
method was employed. The analysis of the elution is shown in figure 15. The numbers
produced by the spectrophotometry seemed to indicate positive results. Therefore, it was
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hoped that this method has succeeded. If this method had worked as planned, pure 18kD
OMP would have been isolated for N-tenninal amino acid sequencing. Although this
method was more effective than the EAH Sepharose method, it was not effective enough

in its ability to purify the 18kD OMP. These results are shown in figures 16 and 17 in the
Western Blot photographs. Figure 16 shows that a higher concentration of the 18kD
OMP was found in the column flow-through than in the actual elution. Some of this
could have been due to incomplete pH neutralization of the elutions. One possible
solution to this would have been dialysis, but it was feared that this would lead to loss of
the protein of interest because of its small size. Although the OMP was visualized using
the light Coomassie stain in figure 16, it did not seem that this band was distinct enough
or clear enough for N-terminal sequencing attempts. Figure 17 shows another Western
Blot using light Coomassie stain in which the OMP127-1-22 joint elution was analyzed
for size and apparent concentration according to the location and brightness of the protein
bands. Again, in this case, it seems that pH problems continue to hinder the effective
migration of the sample down the length of the gel. Perhaps if time had permitted, more
protein preparations would have been tested using affmity chromatography in
conjunction with the 27-1-22 antibody. However, time was limiting and the failed results
were discouraging.
Although attempts at using affmity chromatography were not as successful as one
might have hoped, they have confirmed that the 27-1-22 is a Kappa light chain antibody
and the 18kD OMP does bind to it when tested by immunoblot. A possible way to
improve the results of these experiments might be to find a way to increase the affinity of
the 27-1-22 antibody to the Kappa light chain affmity column and then couple this more
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concentrated eluent to the EAR Sepharose 4B column. This might be more effective in
purifYing the 18kD outer membrane protein. Perhaps more successful results could be
obtained by the use of different elution and binding buffers that would produce optimal
binding and elution of the protein or antibody of interest. Other methods of purification,
such as HPLC, 2D protein gels, or ion-exchange chromatography, might also be more
effective. Because the 18kD OMP is antigenic, it deserves more study as a possible
vaccine component. However, before more study can be done in this area, the protein
must ftrst be more specifically characterized and tested in cattle for antigenic and
immunogenic strength.
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